ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- One-Year Outcomes of Phacoemulsification Combined with Trabecular Micro-Bypass Stent Implantation and Goniosynechialysis in Primary Angle Closure Glaucoma.Journal of clinical medicine · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeTo report real-world intraoperative and early postoperative (< 3 months) complications of iStent surgery and analyze notable examples. PATIENTS AND
methodsThe Manufacturer and User Facility Device Experience database was queried for "iStent" reports from January 2014 to March 2024. Late postoperative events, reports containing inadequate detail, and those from indirect sources (e.g., published literature, social media posts) were excluded. Adverse events were analyzed per device generation.
resultsA total of 808 reports were included, revealing 437, 377, 465, and 48 adverse events across the different iStent generations. The most common intraoperative events were malposition for iStent Trabecular Micro-Bypass, Inject, and Infinite (35%, 40%, 35%) and trocar damage for Inject W (34%). Surgeons and the manufacturer most frequently cited trocar bias as the cause of trocar damage. When the timing of trocar damage was specified, 66.7% occurred during deployment of the final stent of the series. Notably, device-derived foreign body contamination was exclusive to Inject W (11). The most common early postoperative event for all four generations was elevated intraocular pressure (IOP), occurring in 32%, 38%, 15%, and 15% of cases respectively. For the Infinite, hyphema was observed at a comparable proportion (15%).
conclusionPost-market data highlight distinct complication profiles across iStent generations, with malposition and elevated IOP as leading reported issues. Generation-specific trends, such as trocar damage in Inject W and Infinite, underscore the need for tailored surgical vigilance and further study.
Indexed as
Identifiers
41222659What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.